market Inner Banner
  • BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ticker-arrow
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Dr. Lal PathLabs spurts after Q1 PAT rises 27% YoY; extends rally to second day
Back
(12:32, 27 Jul 2026)
Shares of Dr. Lal PathLabs rose 4.27% on Friday, 24 July 2026, after the company reported its Q1 FY27 results. With today's gain, the stock has advanced 10.50% over two trading sessions. It has climbed 31.67% over the last three months and 21.19% over the past one year.

The company's consolidated profit after tax increased 27.2% YoY to Rs 170 crore in Q1 FY27. Revenue from operations increased 19.1% YoY to Rs 798 crore in the quarter ended 30 June 2026.

EBITDA increased 28.7% YoY to Rs 247 crore, while the EBITDA margin expanded 230 basis points YoY to 31.0%. Profit before tax stood at Rs 229 crore in Q1 FY27, up 26.3% YoY.

Material consumed increased 17.8% YoY to Rs 152 crore, while employee benefit expenses rose 7.3% YoY to Rs 133 crore. Fees paid to collection centres increased 20.8% YoY to Rs 116 crore, while other expenses rose 16.3% YoY to Rs 150 crore.

Operationally, the company served 8.2 million patients, up 8.2% YoY, while samples processed increased 10.7% YoY to 25.9 million. SwasthFit contributed 27% of revenue during the quarter, unchanged from a year ago.

The board declared an interim dividend of Rs 5 per equity share for FY27. The record date for the dividend is 30 July 2026.

During the quarter, the company acquired an 80% equity stake in Sunshine Healthcare Limited, Ghana, a diagnostics business, for a consideration not exceeding GHS 45.6 million. It also acquired a 30% equity stake in Neuome Technologies, a company engaged in sample preservation and biobanking solutions, for a consideration not exceeding Rs 3.5 crore.

Cash and cash equivalents stood at Rs 1,693 crore as of 30 June 2026.

During the post-results conference call, management upgraded the company's FY27 revenue growth guidance to the mid-teens from the earlier early-teens forecast. It maintained its FY27 EBITDA margin guidance at 27-28%, adding that any margin outperformance is likely to be reinvested to support future growth. The company also said patient volume growth of 8.2% in Q1 exceeded its initial full-year guidance of 6-7%.

The company has earmarked Rs 140-150 crore for capital expenditure in FY27. It plans to use its Rs 1,693 crore cash balance primarily for acquisitions and expanding its high-end radiology network. Management also said there are no immediate plans for a broad-based price hike and that the benefit from the CGHS price revision is expected to continue for another 2-3 quarters.

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. As on 31 March 2026 the company has 312 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 7,727 Patient Service Centers (PSCs) and 13,935 Pick-up Points (PUPs).

Powered by Capital Market - Live News

Top
Scores
Scores 2.O
Online Dispute Redressal (ODR)
Investor Charter
Invester Complaint
Advisory for Investors
Liquidity Enhancement Scheme
KYC documents in vernacular languages
KYC documents in vernacular languages of commodities
.
Stock Broker Name Registration Number Registered Address Branch Address Contact Number Email id
DB (International) Stock Brokers Limited INZ000179035 (BROKING)

IN-DP-CDSL-266-2004 (DEPOSITORY) 		Unit No. 210/211/211A at 2nd floor, Dalal Street Commercial Cooperative Society Ltd, Block No.53, Zone 5, Gift City, Gandhinagar, Gujarat-382355
51, Mini Market T/F Mandir Wali Gali, Yusaf Sarai, New Delhi 110016 011-35936102 greenpark@dbonline.in
C-12, DB Plaza, RDC Raj Nagar, Ghaziabad 201002 0120-4150393 ghaziabad@dbonline.in
Plot No 4, Wasme House, Film City Sector 16A, Noida – 201301 0120-4823200 compliance@dbonline.in
Out Side Jassusar Gate, Bikaner, Rajasthan – 334001 9001643408 bikaner@dbonline.in
Office No 101, City Center, Opp. High Court, M G Road, Indore 452001 9424083019 brajeshsadani@dbonline.in
203, Marshal House 25, Strand Road, Kolkata 700001 033-40055270 b032@dbonline.in
Shop No.-7, 2nd Floor, Amar Complex, Opp. Hanumaan Mandir, The Mall, Solan- 173212 6230604596 parwanoo@dbonline.in
Daga Commodities Private Limited INZ000028833 114, New Delhi House, 27 Barakhamba Road, Delhi 110001- 0120-4823200 compliance@dbonline.in
Daga Business (International) Stock Brokers (IFSC) Private Limited INZ000202436 Unit No. 228, Signature Building, Second Floor, Block 13B, Zone-1, Gift SEZ, Gandhinagar, Gujarat 382355 - 0120-4823200 compliance@dbonline.in

Disclosure regarding proprietary trading:

As required under Circular No. SEBI/MRD/SE/Cir-42/2003 dated 19.11.2003 issued by the Securities and Exchange Board of India; We hereby disclose that in addition to client based business, We are also doing proprietary trading.

Investor Grievances Email ID: investorgrievance@dbonline.in


Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)
Attention Investors ::
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries | Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. | Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month........... Issued in the interest of Investors"